ArticleJBMR plus2026

Burosumab as bridging therapy in autosomal dominant hypophosphatemic rickets with femoral fracture nonunion and iron deficiency.

Matej Rakusa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.